Af­ter Covid set­back, Val­ne­va lines up $100M for Pfiz­er-al­lied Ly­me dis­ease PhI­II

Val­ne­va has se­cured €102.9 mil­lion (around $99.9 mil­lion USD) in a share of­fer­ing to push for­ward its Pfiz­er-part­nered Ly­me dis­ease vac­cine and a jab for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.